The infectious disease drug developer has applied to float in Hong Kong, which will enable the WuXi AppTec-backed 6 Dimensions Capital to exit.

Brii Biosciences, a China-based chronic disease therapy developer backed by pharmaceutical group WuXi AppTec, has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange. The offering’s lead underwriters are Morgan Stanley Asia and UBS Hong Kong. Although its size and timeline are not yet disclosed, Bloomberg reported in August 2020 the…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.